Introduction {#j_jccm-2019-0017_s_001}
============

Hippocrates, the "Father" of modern medicine, was convinced that disease was a result of multiple factors, including the patient's lifestyle, environmental forces and diet. Accordingly, as these are unique for every individual, treatment should be focused on the individual. He stated that because the organism acts as one, it should be treated as one, and not as individual parts of a bigger system.

In recent times, a new form of medicine has become increasingly exercised, namely personalised medicine (PM) and is efficacious in many medical specialities.

Several biomarkers with the potential for diagnosis and prognosis of different field-specific conditions, such as hypertension, atherosclerosis, and coronary bypass surgery, have already been identified as useful in cardiovascular PM medicine \[[@j_jccm-2019-0017_ref_001],[@j_jccm-2019-0017_ref_002]\]. Oncology is another field in which PM is already widely implemented. A wide array of biomarkers are specific for different types of neoplasms and their evolution, allowing for the treatment of different forms of neoplasm to be tailored to the individual. Biomarkers, specific for melanomas \[[@j_jccm-2019-0017_ref_003]\], breast cancer \[[@j_jccm-2019-0017_ref_004]\], renal cancer \[[@j_jccm-2019-0017_ref_005]\], gastrointestinal disorders \[[@j_jccm-2019-0017_ref_006]\] orthopaedics \[[@j_jccm-2019-0017_ref_007]\], and postoperative care \[[@j_jccm-2019-0017_ref_008]\] have been employed these areas.

Pharmacogenomic biomarkers are currently accepted as key components in drug labelling.

[Table 1](#j_jccm-2019-0017_tab_001){ref-type="table"}. list the drugs and also the biomarkers which are related to those drugs.

###### 

Table of Pharmacogenomic Biomarkers in Drug Labeling (10)

  Medical area                  Drug                            Biomarker
  ----------------------------- ------------------------------- ------------------------------------------------------------------------------------------
  Infectious                    Abacavir                        HLA-B
  Diseases                      Boceprevir                      IFNL3 (IL28B)- genetic variant near the gene encoding interferon-lambda-3
                                Ceftriaxone                     G6PD
                                Daclatasvir                     IFNL3 (IL28B)
                                Efavirenz                       CYP2B6
                                                                
  Oncology                      Abemaciclib (1)                 ESR (HR)-hormone receptor
                                Abemaciclib (2)                 ERBB2 (HER2)- , human epidermal growth factor receptor 2
                                                                ERBB2 (HER2)
                                Ado-Trastuzumab Emtansine       EGFR (epidermal growth factor receptor)
                                Afatinib                        ALK (anaplastic lymphoma kinase)
                                Alectinib                       CD274 (PD-L1)
                                Atezolizumab (1)                Gene Signature (T-effector)
                                Atezolizumab (2)                ROS
                                Crizotinib                      BRAF
                                Dabrafenib                      RAS
                                Dabrafenib                      ESR, PGR (Hormone Receptor)
                                Docetaxel                       CD274 (PD-L1)
                                Durvalumab                      Chromosome 17p
                                Duvelisib                       FLT3
                                Gilteritinib                    Chromosome 11q
                                Ibrutinib                       BCR-ABL1 (Philadelphia chromosome)
                                Inotuzumab Ozogamicin           Microsatellite Instability Mismatch Repair
                                Ipilimumab                      IDH1- isocitrate dehydrogenase-1
                                Ivosidenib                      HLA-DQA1, HLA-DRB1
                                Lapatinib                       NTRK- gene
                                Larotrectinib                   NUDT15- nucleotide diphosphatase
                                Mercaptopurine                  UGT1A1-polymorphysm
                                                                
  Neurology                     Amifampridine                   NAT2 (N-acetyltransferase 2)
                                Citalopram                      CYP2C19
                                Inotersen                       TTR
                                Nusinersen                      Nusinersen
                                                                
  Psychiatry                    Amphetamine                     CYP2D6
                                Clozapine                       CYP2D6
                                                                
  Anesthesiology                Articaine and Epinephrine (1)   G6PD
                                Chloroprocaine                  G6PD
                                Codeine                         CYP2D
                                Lidocaine and Tetracaine        G6PD
                                Lofexidine                      CYP2D6
                                Mivacurium                      BCHE
                                                                
  Hematology                    Avatrombopag (1)                F2 (Prothrombin)
                                Avatrombopag (2)                F5 (Factor V Leiden)
                                Avatrombopag (3)                SERPINC1 (Antithrombin III)
                                Blinatumomab                    BCR-ABL1 (Philadelphia chromosome)
                                Emapalumab-lzsg                 PRF1, RAB27A, SH2D1A, STXBP2, STX11, UNC13D, XIAP (Hemophagocy tic Lymphohistiocytosis)-
                                                                
                                Enasidenib                      IDH2
                                Lenalidomide                    Chromosome 5q
                                Lusutrombopag                   PROC, SERPINC1 (Antithrombin III)
                                                                
  Inborn Errors of Metabolism   Cerliponase Alfa                TPP1- tripeptidyl peptidase 1
                                Eliglustat                      CYP2D6
                                Migalastat                      GLA- galactosidase alpha gene
                                                                
  Urology                       Fesoterodine                    CYP2D6
                                Tolterodine                     CYP2D6
                                                                
  Pulmonary                     Formoterol                      CYP2D6
                                                                CYP2C19
                                Ivacaftor                       CFTR- cystic fibrosis transmembrane conductance regulator
                                                                
  Gynecology                    Ospemifene                      CYP2C9

They include germline or somatic gene variants, functional deficiencies with a genetic aetiology, gene expression differences, and chromosomal abnormalities; selected protein biomarkers that are used to select treatments for patients are also included \[[@j_jccm-2019-0017_ref_009]\].

PM is also well established in the field of genetics, where a vast array of biomarkers can be employed to identify specific modifications and facilitate in choosing a suitable treatment approach \[[@j_jccm-2019-0017_ref_010]\]. Current emphasis focuses on advances in genetic testing and biomarker identification. The possibility of creating a patient's "omic" (vide infra) appraisal and then using this data and information, establish a remarkable and unprecedented opportunity to develop individualised treatment strategies \[[@j_jccm-2019-0017_ref_011]\].

PM is an integration of complete biological systems which aims to create a stratified medicine with personalised care. Most medical doctors are working at the phenome level when treating a specific disease, be it cancer, cardiovascular conditions or psychiatric disorders. Occasionally treatment is extended to the genome level, which can identify rare variations of DNA or other genomic rearrangements. There are other "omes" zones including epigenome, transcriptome, proteome, metabolome though these are less commonly used. These zones contain tremendous information which could be utilised in treating the individual instead of the disease \[[@j_jccm-2019-0017_ref_010]\].

Personalised medicine is about using data on multiple scales, and having the ability to create a digital human mapping, with superimposed layers which includes, among other things, social graphs, biosensors, imaging for anatomy description, the characteristics of various "omics" such as genomics, DNA sequencing, transcriptomics, proteomics, metabolomics, and epigenomics. All these layers are wrapped in the non-genetic totality of human environment, the exposome \[[@j_jccm-2019-0017_ref_011]\]. All these elements allow the creation of a unique genetic print for every patient, individualised, a non-repetitive print on which future medical decisions could be based.

Personalised Medicine in ICU {#j_jccm-2019-0017_s_002}
============================

It is customary in today's approach to treatment, to create both standardise diagnosis and therapies. There are published guidelines and protocols, which are undeniably essential, but which in many instances do no more than to justify current therapeutic mindsets and approaches. At times, even existing legislative frameworks cannot solve every patient's problems. A change is needed to modify the baseline approach toward that of personalised, preventive, predictive, pharmacotherapeutics and patient participatory medicine.

Recent studies have classified ICU syndromes into subtypes. One way of creating these subtypes was by gene expression analysis, which helped differentiate sepsis from non-septic states \[[@j_jccm-2019-0017_ref_012]\] and also in estimating the likeliness of those subtypes to respond to specific treatments \[[@j_jccm-2019-0017_ref_013]\].

Specific genes were sequenced to identify single nucleotide polymorphisms associated with different outcomes in both sepsis and ARDS \[[@j_jccm-2019-0017_ref_014], [@j_jccm-2019-0017_ref_015]\]. In genome-wide association studies (GWAS) of sepsis and ARDS, consideration was given to adding precision and other pharmcogenes to the list of drugs used in sepsis \[[@j_jccm-2019-0017_ref_016]\]. Beyond genomics, precision medical information has been subtracted from other data types. Serum biomarkers have shown to be useful in differentiating septic patients with or without ARDS as well as classifying ARDS. \[[@j_jccm-2019-0017_ref_017]\] The recent identification of critical illness subtypes points to an emerging need for relating them to precise therapies. However, despite new advances in this new area of medicine, precision therapies in the ICU are at present, neither clearly defined nor generally accepted.

Data for Personalised Medicine {#j_jccm-2019-0017_s_003}
==============================

Data concerning medical history and various prescribed treatments for each patient should be contained in an electronic patient health record (EHR). The ability to process such information is impeded by the sheer size of these data and requires the involvement of medical specialists working in conjunction with the latest computer technology. In order to achieve this goal, computer models are required to help clinicians organise the data, recognise patterns, and interpret results allowing the creation of specific models which could then be used for tailoring distinctive treatments for individual patients.

This "big data" in medicine is expected to have a significant role in pharmacogenetics and stratified healthcare. Nowadays, patients are treated in large cohorts based on their common diagnosis. However, each individual is different and can and will react differently to the specific treatment of a distinct disease \[[@j_jccm-2019-0017_ref_018], [@j_jccm-2019-0017_ref_019], [@j_jccm-2019-0017_ref_020]\].

There is ongoing research in this respect, one example being the Pan-Cancer project, initiated by the Cancer Genome Atlas research network which aims to analyse a multitude of tumour types and molecular modifications in cancer types, and to provide a starting point for newer discoveries in the field \[[@j_jccm-2019-0017_ref_018]\]. Other examples are the Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer projects which provide vast genomic databases for cancer cell abnormalities and their response to specific treatments \[[@j_jccm-2019-0017_ref_019], [@j_jccm-2019-0017_ref_020]\].

The MIMIC III database, a registry used to extract and process data for retrospective analysis, is a useful data registry created for use in ICU \[[@j_jccm-2019-0017_ref_021]\].

However, having raw data sets in not enough. These data need validation, storage, protection and specific processing in order to be useful for the creation of individualised treatments. To meet these requirements, suitable infrastructures and specialists are required \[[@j_jccm-2019-0017_ref_022]\].

The prerequisite to creating an EHR is that all data relating to a patient be combined and gathered in a single virtual file which can be accessed when a piece of medical information is needed. In creating an EHR, a joint effort is needed on the part of the patient, the medical specialists and different branches of research and informatics. ([Figure 1](#j_jccm-2019-0017_fig_001){ref-type="fig"})

![Big data circuit](jccm-05-090-g001){#j_jccm-2019-0017_fig_001}

There are sensitive issues in developing the bio-informatics, not the least involving the protection of data. Bioinformatics requires that a patient's specific medical data are known in order to have all the "necessary ingredients" for preparing a specific if not unique treatment plan. This requirement may contravene existing data protection policies. For succeeding in creating a patient data bank, an interdisciplinary team is needed. As stated above, such a team should comprise, in addition to clinicians and IT specialists, ethicists and patient representatives.

Personalised Medicine in Sepsis {#j_jccm-2019-0017_s_004}
===============================

Sepsis is a systemic inflammatory response to infection, ranging from systemic inflammatory response syndrome (SIRS) to septic shock and multiple organ dysfunction syndromes (MODS). Sepsis is the single most encountered cause of death in intensive care patients \[[@j_jccm-2019-0017_ref_023]\].

Different stages of sepsis lead to different dysfunctions, which are present systemically. SIRS determines endothelial dysfunction, impairment of microcirculation, hypoxia, apoptosis, multiple organ failure and death \[[@j_jccm-2019-0017_ref_024]\]. Sepsis, as a syndrome, is comprised of a cascade of pro and anti-inflammatory cytokines and mediators in the systemic circulation which are found at different stages of sepsis. Examples of the most common inflammatory cytokines in sepsis are tumour necrosis factor-α(TNF-α), interleukin-1 (IL-1) and pro-inflammatory cytokines IL-6 and IL-8. They are released by activating macrophages and CD4 T cell within the first hour after infection. To counteract and also to prevent severe damage, anti-inflammatory mediators such as IL-10, IL-13, IL-14, and transforming growth factor-β (TGF-β), are also released \[[@j_jccm-2019-0017_ref_025]\].

Immunomodulatory therapies in which patients are prescribed corticosteroids, anti-TNF-αantibodies, anti-interleukin antibodies, platelet-activating factor (PAF) antagonists, antioxidants, as well as the use of selenium modulation of coagulation and complement pathway, have been accepted as beneficial \[[@j_jccm-2019-0017_ref_026], [@j_jccm-2019-0017_ref_027], [@j_jccm-2019-0017_ref_028], [@j_jccm-2019-0017_ref_029], [@j_jccm-2019-0017_ref_030], [@j_jccm-2019-0017_ref_031], [@j_jccm-2019-0017_ref_032]\], and indeed, some of these strategies proved to be efficacious upon septic patients survival of \[[@j_jccm-2019-0017_ref_033]\].

The clinical evolution characteristics of sepsis make both diagnosis and treatment difficult because patients proceed through different stages of sepsis, with each stage requiring treatment specifically targeted to counteract these variations. Sepsis patients are still treated as groups not as individuals, even though there are reported examples of treatment which are proven to be efficacious for septic patients but not others \[[@j_jccm-2019-0017_ref_034]\].

Seymour et al. (2016) outlined revised sepsis definitions based on large data sets obtained from several ICUs. This is seen as an initial step forward towards PM in the management of sepsis \[[@j_jccm-2019-0017_ref_034]\].

Prompt diagnosis and treatment of sepsis are crucial to reducing mortality. The mortality risk increases with every hour of delay in diagnosis and commencement of appropriate therapy. Prognostic scores are now used to assess mortality risk. The widely accepted Sequential Organ Failure Assessment (SOFA) score, assesses the severity of organ dysfunction in patients assumed to be septic \[[@j_jccm-2019-0017_ref_034]\]. However, because of the complexity of the method and the need of a large amount of medical data relating to the patient, which are not always available a new prognosis score, "quick SOFA" has been proposed. This scoring system is simplified, containing only three variables, and is targeted to ease the identification of septic patients at risk of death \[[@j_jccm-2019-0017_ref_034]\].

The main shortcoming in sepsis diagnosis is that there is no "gold standard" blood test, which can identify patients with infections before results become available from standard microbiological cultures.

The ongoing search for new therapies for sepsis and new prognostic and diagnostic biomarkers has generated several dozen microarray-based genome-wide expression studies over the past decade, variously focusing on the diagnosis, prognosis, pathogen response, and underlying sepsis pathophysiology. Despite tremendous gains in the understanding of gene expression in sepsis, few insights have translated to improvements in clinical practice \[[@j_jccm-2019-0017_ref_035], [@j_jccm-2019-0017_ref_036]\].

Most of the studies which were conducted on sepsis treatment had not ended with significant results regarding the survival of septic patients when the enrolment was based on heterogeneous groups of patients \[[@j_jccm-2019-0017_ref_037],[@j_jccm-2019-0017_ref_038]\].

Conclusion {#j_jccm-2019-0017_s_005}
==========

Precision medicine seeks to recognise the patient as an individual, as unique, using modern technology to store, access and analyse the vast amount of medical data.

Precision medicine is the future treatment approach in ICU, especially in sepsis treatment. The fact that patients respond differently to treatment procedures should be regarded as a starting point in the treatment of an individual.
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